|
KMID : 1134120120150030288
|
|
Journal of Breast Cancer
2012 Volume.15 No. 3 p.288 ~ p.295
|
|
|
Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients
|
|
Yang Li-Heng
Tseng Hsin-Shun
Lin Che
Chen Li-Sheng
Chen Shou-Tung
Kuo Shou-Jen
Chen Dar-Ren
|
|
|
Abstract
|
|
|
Purpose: This study aimed to analyze the efficacy and prognostic significance of adjuvant tamoxifen in breast cancer patients with various hormone receptor statuses.
Methods: Typically, 1,260 female breast cancer patients were recruited in this study. The correlation between estrogen receptor (ER)/progesterone receptor (PR) phenotypes and clinical characteristics was investigated, and the survival rate was assessed after 5-year follow-up.
Results: The 5-year overall survival (85%) was better in women under the age of 50 years. Patients with ER+/PR+ tumors had a better 5-year survival rate (94%); those with ER-/PR- tumors experienced the worst outcome (74% survival rate); whereas single-positive cases were in between. In 97 out of 128 patients with ER-/PR+ tumors, tamoxifen was given as adjuvant hormonal therapy, and it increased the survival benefit in the lower grade group in terms of overall survival and disease-free survival (p=0.01 and p=0.03, respectively).
Conclusion: For high-grade tumors with ER-/PR+, adjuvant tamoxifen therapy may have no survival benefit, whereas for the patients with low-grade ER-/PR+ tumors, adjuvant tamoxifen therapy is highly suggestive.
|
|
|
KEYWORD
|
|
|
Breast carcinoma, Estrogen receptor, Progesterone receptor, Tamoxifen
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|